Hyku
Lexington
About Hyku
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins. The Hyku platform identifies molecules that covalently bind non-cysteine amino acids to aid in the creation of innovative medicines that can address present issues with a variety of disease targets, such as selectivity, druggability, and resistance.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $56.0M
- Funding stage: Seed
- Last round: Seed (Sep 2023)
- Website: hykubiosciences.com
Industries & Categories
Biopharma, Biotechnology, Life Science
Canonical: https://fsome.com/organization/hyku-63226 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.